| Objective:Paclitaxel combined with platinum can be used as the first-line treatment for advanced esophageal carcinoma,but common paclitaxel can cause allergic reaction and toxic organ damage due to the sensitizing effect of its solvent.Therefore,this study is to explore the efficacy and safety of paclitaxel liposome combined with nedaplatin biweekly regimen in the first-line treatment of patients with advanced esophageal carcinoma.Methods:Thirty-seven advanced esophageal carcinoma patients with evaluable lesions who received paclitaxel liposome combined with nedaplatin biweekly regimen at Cancer Hospital of the Chinese Academy of Medical Sciences from April 2016 to December 2018 were retrospectively analyzed.The primary endpoint was the overall response rate(ORR),disease control rate(DCR),overall survival(OS)and progress free survival(PFS),and the secondary end point was to evaluate the safety profile of the patient.Results:The median follow-up time of all patients was 17.1 months,the median chemotherapy cycle was 5,and the ORR was 43.2%(16/37),including 16 patients evaluated as partial response(PR)and 10 patients evaluated as stable disease(SD).The disease control rate was 70.3%.mOS and mPFS were 11.3(95%CI:9.3-13.3)months and 3.5(95%CI:1.1-6.0)months for all patients.The common adverse reactions were myelosuppression,the incidence of grade 3-4 leucopenia was 18.9%,and the incidence of grade 3-4 neutropenia was 24.3%,which all returned to normal after symptomatic treatment.No neurotoxicity or allergic reaction occurred in the patients,and the patients were well tolerated.Conclusions:The efficacy of paclitaxel liposome combined with nedaplatin in the first-line treatment of advanced esophageal carcinoma is definite,with good safety and tolerability.Background:To explore the clinical characteristics of programmed death protein-1(PD-1)antibody SHR-1210 as a single agent or combined with apatinib and chemotherapy in the treatment of patients with advanced esophageal squamous cell carcinoma with abnormal liver function.Methods:Analyze the clinical data and liver function indicators of 73 patients with esophageal squamous cell carcinoma in 2 prospective clinical studies conducted at the Cancer Hospital of the Chinese Academy of Medical Sciences from May 11,2016,to November 19,2019,including aspartate amino transfer Changes in enzymes,alanine aminotransferase,and bilirubin.Results:There were 35 patients with abnormal liver function during the research and treatment process,including 13 patients in the monotherapy group which the median time to the first occurrence of abnormal liver function was 55 days,and 22 patients in the combination group,the median time to the first occurrence of abnormal liver function was 41 days.There were 2 cases with clinical symptoms,including fatigue,loss of appetite,and jaundice.Among the 35 patients with abnormal liver function,28 patients returned to normal liver function,7 patients with liver function improved to Grade 1,and no patients were seriously life-threatening or died due to liver function abnormalities.Conclusions In this study,the degree of liver function abnormality in most patients is mild,and after symptomatic treatment,liver function can return to normal or improve.During the administration of PD-1 antibody SHR-1210,attention should be paid to patients with combined targeting and chemotherapy.For patients with a history of long-term smoking,drinking,and hepatitis B virus infection,timely monitoring of liver function and active treatment. |
